BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Disitamab Vedotin readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Disitamab Vedotin\, from ClinicalTrials.g
 ov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06221748-2454@assetmemo.bio
DTSTAMP:20261121T005658Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Disitamab Vedotin: Phase 2/3 readout est. (NCT06221748)
DESCRIPTION:Disitamab Vedotin\, phase 2/3\, Gastric Cancer.\nStudy: DV Comb
 ined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and 
 Gastroesophageal Junction Adenocarcinoma After Progression on First-line T
 herapy\nEstimated primary completion: December 2026. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06221748
URL:https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05831878-2454@assetmemo.bio
DTSTAMP:20261121T005658Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Disitamab Vedotin: Phase na readout est. (NCT05831878)
DESCRIPTION:Disitamab Vedotin\, phase na\, HR+/HER2- Metastatic Breast Canc
 er.\nStudy: RC48-ADC in HER2-low Advanced Breast Cancer\nEstimated primary
  completion: December 2026. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/disitamab-vedotin#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT05831878
URL:https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06660511-2454@assetmemo.bio
DTSTAMP:20261121T005658Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Disitamab Vedotin: Phase 1 readout est. (NCT06660511)
DESCRIPTION:Disitamab Vedotin\, phase 1.\nStudy: Exploratory Study on the S
 afety and Efficacy of Disitamab Vedotin in Combination With Anlotinib Hydr
 ochloride for the Treatment of HER-2-expressing Recurrent Platinum-resista
 nt Ovarian Cancer.\nEstimated primary completion: 1 December 2026. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/disitamab-vedotin#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT06660511
URL:https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07446452-2454@assetmemo.bio
DTSTAMP:20261121T005658Z
DTSTART;VALUE=DATE:20261206
DTEND;VALUE=DATE:20261207
SUMMARY:Disitamab Vedotin: Phase 2 readout est. (NCT07446452)
DESCRIPTION:Disitamab Vedotin\, phase 2\, HR+/HER2- Metastatic Breast Cance
 r.\nStudy: Disitamab Vedotin Plus Bevacizumab in HER2-Low Metastatic Breas
 t Cancer After T-DXd Failure: A Phase II Study\nEstimated primary completi
 on: 6 December 2026. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 disitamab-vedotin#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07446452
URL:https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04879329-2454@assetmemo.bio
DTSTAMP:20261121T005658Z
DTSTART;VALUE=DATE:20261211
DTEND;VALUE=DATE:20261212
SUMMARY:Disitamab Vedotin: Phase 2 readout est. (NCT04879329)
DESCRIPTION:Disitamab Vedotin\, phase 2\, Urothelial Carcinoma.\nStudy: A S
 tudy of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer
  That Expresses HER2\nEstimated primary completion: 11 December 2026. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/disitamab-vedotin#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT04879329
URL:https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07093866-2454@assetmemo.bio
DTSTAMP:20261121T005658Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Disitamab Vedotin: Phase 2 readout est. (NCT07093866)
DESCRIPTION:Disitamab Vedotin\, phase 2.\nStudy: Efficacy and Safety of Dis
 itamab Vedotin Plus Abiraterone for Metastatic Castration-Resistant Prosta
 te Cancer：a Phase II Study\nEstimated primary completion: 30 December 20
 26. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/disitamab-vedotin
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT070
 93866
URL:https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06730373-2454@assetmemo.bio
DTSTAMP:20261121T005658Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Disitamab Vedotin: Phase 2 readout est. (NCT06730373)
DESCRIPTION:Disitamab Vedotin\, phase 2\, Gastric Cancer.\nStudy: First-lin
 e Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (
 RCTS2)\nEstimated primary completion: 31 December 2026. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT06730373
URL:https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05302284-2454@assetmemo.bio
DTSTAMP:20261121T005658Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Disitamab Vedotin: Phase 3 readout est. (NCT05302284)
DESCRIPTION:Disitamab Vedotin\, phase 3\, Urothelial Carcinoma.\nStudy: A S
 tudy of RC48-ADC Combined With Toripalimab For First-line Treatment of Uro
 thelial Carcinoma\nEstimated primary completion: 31 December 2026. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/disitamab-vedotin#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT05302284
URL:https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06791070-2454@assetmemo.bio
DTSTAMP:20261121T005658Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Disitamab Vedotin: Phase 2 readout est. (NCT06791070)
DESCRIPTION:Disitamab Vedotin\, phase 2.\nStudy: A Study of RC48-ADC Combin
 ed With JS001 for Advanced Extramammary Paget Disease of the Scrotum\nEsti
 mated primary completion: January 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/disitamab-vedotin#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT06791070
URL:https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06904573-2454@assetmemo.bio
DTSTAMP:20261121T005658Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Disitamab Vedotin: Phase 2 readout est. (NCT06904573)
DESCRIPTION:Disitamab Vedotin\, phase 2\, Urothelial Carcinoma.\nStudy: Pro
 biotics in Advanced Urothelial Carcinoma\nEstimated primary completion: 1 
 January 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/disitam
 ab-vedotin#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06904573
URL:https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07285941-2454@assetmemo.bio
DTSTAMP:20261121T005658Z
DTSTART;VALUE=DATE:20270104
DTEND;VALUE=DATE:20270105
SUMMARY:Disitamab Vedotin: Phase 2 readout est. (NCT07285941)
DESCRIPTION:Disitamab Vedotin\, phase 2.\nStudy: Efficacy and Safety of Dis
 tamab Vedotin Combined With Carboplatin for Advanced Ovarian Cancer in the
  First Line Treatment\nEstimated primary completion: 4 January 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/disitamab-vedotin#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07285941
URL:https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05911295-2454@assetmemo.bio
DTSTAMP:20261121T005658Z
DTSTART;VALUE=DATE:20270129
DTEND;VALUE=DATE:20270130
SUMMARY:Disitamab Vedotin: Phase 3 readout est. (NCT05911295)
DESCRIPTION:Disitamab Vedotin\, phase 3\, Urothelial Carcinoma.\nStudy: Dis
 itamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated 
 Urothelial Cancer Expressing HER2\nEstimated primary completion: 29 Januar
 y 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/disitamab-ved
 otin#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T05911295
URL:https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07591805-2454@assetmemo.bio
DTSTAMP:20261121T005658Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Disitamab Vedotin: Phase 2 readout est. (NCT07591805)
DESCRIPTION:Disitamab Vedotin\, phase 2\, Urothelial Carcinoma.\nStudy: HER
 O-UTUC: Intravesical RC48 After RNU for HER2+ UTUC\nEstimated primary comp
 letion: 31 January 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/disitamab-vedotin#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07591805
URL:https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07172217-2454@assetmemo.bio
DTSTAMP:20261121T005658Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Disitamab Vedotin: Phase 2 readout est. (NCT07172217)
DESCRIPTION:Disitamab Vedotin\, phase 2.\nStudy: The Efficacy and Safety RC
 48 Plus QL1706 in Second-Line Treatment of HER2-Expressing Recurrent CC\nE
 stimated primary completion: 28 February 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/disitamab-vedotin#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07172217
URL:https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07646145-2454@assetmemo.bio
DTSTAMP:20261121T005658Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Disitamab Vedotin: Phase 2 readout est. (NCT07646145)
DESCRIPTION:Disitamab Vedotin\, phase 2.\nStudy: Disitamab Vedotin Plus Int
 ravesical Mitomycin C in HER2-Expressing Intermediate- to High-Risk Non-Mu
 scle-Invasive Bladder Cancer\nEstimated primary completion: April 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/disitamab-vedotin#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07646145
URL:https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06385873-2454@assetmemo.bio
DTSTAMP:20261121T005658Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:Disitamab Vedotin: Phase 2 readout est. (NCT06385873)
DESCRIPTION:Disitamab Vedotin\, phase 2\, Gastric Cancer.\nStudy: RC48 Comb
 ined With Adebrelimab\, Apatinib and S-1 as Neoadjuvant Therapy in Locally
  Advanced Gastric Cancer\nEstimated primary completion: 1 May 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/disitamab-vedotin#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06385873
URL:https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06420973-2454@assetmemo.bio
DTSTAMP:20261121T005658Z
DTSTART;VALUE=DATE:20270517
DTEND;VALUE=DATE:20270518
SUMMARY:Disitamab Vedotin: Phase 2 readout est. (NCT06420973)
DESCRIPTION:Disitamab Vedotin\, phase 2.\nStudy: RC48 Treatment for Platinu
 m Sensitive Recurrent Ovarian Cancer With HER2 Expression\nEstimated prima
 ry completion: 17 May 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/disitamab-vedotin#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT06420973
URL:https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06663007-2454@assetmemo.bio
DTSTAMP:20261121T005658Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Disitamab Vedotin: Phase 1/2 readout est. (NCT06663007)
DESCRIPTION:Disitamab Vedotin\, phase 1/2.\nStudy: RC48 Monotherapy or Comb
 ination With Envafolimab for CDK12 Alterations mCRPC With Standard Treatme
 nt Failure\nEstimated primary completion: 31 May 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT06663007
URL:https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07159217-2454@assetmemo.bio
DTSTAMP:20261121T005658Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Disitamab Vedotin: Phase 2 readout est. (NCT07159217)
DESCRIPTION:Disitamab Vedotin\, phase 2.\nStudy: Disitamab Vedotin Plus Len
 vatinib and PD-1 Inhibitors for Treating HER2-positive Advanced Biliary Tr
 act Cancer\nEstimated primary completion: 31 May 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07159217
URL:https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06734182-2454@assetmemo.bio
DTSTAMP:20261121T005658Z
DTSTART;VALUE=DATE:20270622
DTEND;VALUE=DATE:20270623
SUMMARY:Disitamab Vedotin: Phase 2 readout est. (NCT06734182)
DESCRIPTION:Disitamab Vedotin\, phase 2\, Non-Small Cell Lung Cancer.\nStud
 y: Neoadjuvant Envafolimab Plus Disitamab Vedotin and Carboplatin in Resec
 table HER2-Mutant Non-Small-Cell Lung Cancer\nEstimated primary completion
 : 22 June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/disit
 amab-vedotin#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT06734182
URL:https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06155396-2454@assetmemo.bio
DTSTAMP:20261121T005658Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Disitamab Vedotin: Phase 2 readout est. (NCT06155396)
DESCRIPTION:Disitamab Vedotin\, phase 2.\nStudy: A Study of RC48-ADC Combin
 ation With Zimberelimab Injection Therapies at Least First-line Platinum-c
 ontaining Standard Therapy Failed With Recurrent or Metastatic Cervical Ca
 ncer\nEstimated primary completion: 30 June 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT06155396
URL:https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07720921-2454@assetmemo.bio
DTSTAMP:20261121T005658Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:Disitamab Vedotin: Phase 2 readout est. (NCT07720921)
DESCRIPTION:Disitamab Vedotin\, phase 2\, Urothelial Carcinoma.\nStudy: Neo
 adjuvant Disitamab Vedotin\, Toripalimab\, and Radiotherapy for High-risk 
 UTUC ( LUXUS07.1 )\nEstimated primary completion: 1 August 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/disitamab-vedotin#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07720921
URL:https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07151560-2454@assetmemo.bio
DTSTAMP:20261121T005658Z
DTSTART;VALUE=DATE:20270830
DTEND;VALUE=DATE:20270831
SUMMARY:Disitamab Vedotin: Phase 2 readout est. (NCT07151560)
DESCRIPTION:Disitamab Vedotin\, phase 2.\nStudy: Efficacy and Safety of Two
  Bladder-preserving Treatment Durations With Disitamab Vedotin Plus Toripa
 limab Combination in Her2-expressing Muscle-invasive Bladder Cancer: A Pha
 se II\, Open-Label\, Randomized Clinical Trial\nEstimated primary completi
 on: 30 August 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/d
 isitamab-vedotin#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07151560
URL:https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07783815-2454@assetmemo.bio
DTSTAMP:20261121T005658Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Disitamab Vedotin: Phase 1 readout est. (NCT07783815)
DESCRIPTION:Disitamab Vedotin\, phase 1.\nStudy: A Study to Evaluate the Ef
 ficacy and Safety of Intravesical Instillation of Disitamab Vedotin Combin
 ed With Toripalimab in Patients With HER2-Positive High-Risk Non-Muscle In
 vasive Bladder Cancer Who Are BCG-Naïve or Have BCG Failure\nEstimated pr
 imary completion: 1 September 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/disitamab-vedotin#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07783815
URL:https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06560528-2454@assetmemo.bio
DTSTAMP:20261121T005658Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Disitamab Vedotin: Phase 2 readout est. (NCT06560528)
DESCRIPTION:Disitamab Vedotin\, phase 2\, Gastric Cancer.\nStudy: Disitamab
  Vedotin Combined With Tislelizumab and Capecitabine in the Perioperative 
 Treatment of Locally Advanced Gastric Cancer With HER2 Overexpression\nEst
 imated primary completion: 1 September 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/disitamab-vedotin#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06560528
URL:https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07740993-2454@assetmemo.bio
DTSTAMP:20261121T005658Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:Disitamab Vedotin: Phase 2 readout est. (NCT07740993)
DESCRIPTION:Disitamab Vedotin\, phase 2.\nStudy: A Single-Arm Study of Sint
 ilimab and Disitamab Vedotin for Locally Advanced Eyelid Sebaceous Gland C
 arcinoma\nEstimated primary completion: 1 October 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07740993
URL:https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06966453-2454@assetmemo.bio
DTSTAMP:20261121T005658Z
DTSTART;VALUE=DATE:20271025
DTEND;VALUE=DATE:20271026
SUMMARY:Disitamab Vedotin: Phase 1/2 readout est. (NCT06966453)
DESCRIPTION:Disitamab Vedotin\, phase 1/2\, HR+/HER2- Metastatic Breast Can
 cer.\nStudy: A Study of Disitamab Vedotin in Adults With HER2 Expressing A
 dvanced Breast Cancer\nEstimated primary completion: 25 October 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/disitamab-vedotin#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT06966453
URL:https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05917158-2454@assetmemo.bio
DTSTAMP:20261121T005658Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Disitamab Vedotin: Phase 2 readout est. (NCT05917158)
DESCRIPTION:Disitamab Vedotin\, phase 2\, Urothelial Carcinoma.\nStudy: A S
 tudy of RC48-ADC Combined with JS001 for Postoperative Adjuvant Treatment 
 of Upper Tract Urothelial Carcinoma\nEstimated primary completion: Decembe
 r 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/disitamab-ved
 otin#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T05917158
URL:https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05745740-2454@assetmemo.bio
DTSTAMP:20261121T005658Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Disitamab Vedotin: Phase 1/2 readout est. (NCT05745740)
DESCRIPTION:Disitamab Vedotin\, phase 1/2\, Non-Small Cell Lung Cancer.\nSt
 udy: A Study of RC48-ADC Combined With Pyrotinib For Treatment of Local Ad
 vanced or Metastasis NSCLC With HER2 Mutation\nEstimated primary completio
 n: 1 December 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/d
 isitamab-vedotin#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT05745740
URL:https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07279597-2454@assetmemo.bio
DTSTAMP:20261121T005658Z
DTSTART;VALUE=DATE:20271210
DTEND;VALUE=DATE:20271211
SUMMARY:Disitamab Vedotin: Phase 2 readout est. (NCT07279597)
DESCRIPTION:Disitamab Vedotin\, phase 2\, Urothelial Carcinoma.\nStudy: A P
 hase II Study of Toripalimab Plus RC48-ADC With Radiotherapy for Bladder P
 reservation in HER2-Positive Muscle-Invasive Bladder Cancer\nEstimated pri
 mary completion: 10 December 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/disitamab-vedotin#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07279597
URL:https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07117851-2454@assetmemo.bio
DTSTAMP:20261121T005658Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Disitamab Vedotin: Phase 2 readout est. (NCT07117851)
DESCRIPTION:Disitamab Vedotin\, phase 2.\nStudy: A Study of Disitamab Vedot
 in + Bicalutamide in HER2/AR-Positive Scrotal Paget's Disease\nEstimated p
 rimary completion: 30 December 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/disitamab-vedotin#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07117851
URL:https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07201675-2454@assetmemo.bio
DTSTAMP:20261121T005658Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Disitamab Vedotin: Phase 2 readout est. (NCT07201675)
DESCRIPTION:Disitamab Vedotin\, phase 2.\nStudy: Vedisertib (RC48/ADC) Comb
 ined With Toripalimab in Bladder-preserving Treatment\nEstimated primary c
 ompletion: 30 December 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/disitamab-vedotin#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07201675
URL:https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07311577-2454@assetmemo.bio
DTSTAMP:20261121T005658Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Disitamab Vedotin: Phase 2 readout est. (NCT07311577)
DESCRIPTION:Disitamab Vedotin\, phase 2.\nStudy: Disitamab Vedotin Combined
  With Platinum and Bevacizumab as First-Line and Maintenance Therapy for H
 ER2-Expressing\, HRD-Negative High-Risk Ovarian Cancer: A Multicenter\, No
 n-Randomized\, Single-Arm Phase II Clinical Study\nEstimated primary compl
 etion: 30 December 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/disitamab-vedotin#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07311577
URL:https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07584733-2454@assetmemo.bio
DTSTAMP:20261121T005658Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Disitamab Vedotin: Phase 2 readout est. (NCT07584733)
DESCRIPTION:Disitamab Vedotin\, phase 2\, Urothelial Carcinoma.\nStudy: Bio
 marker-Enriched Kidney-Preserving Strategy With Disitamab Vedotin Plus Tis
 lelizumab in HER2-Positive High-Risk Upper Tract Urothelial Carcinoma\nEst
 imated primary completion: 31 December 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/disitamab-vedotin#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07584733
URL:https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04400695-2454@assetmemo.bio
DTSTAMP:20261121T005658Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Disitamab Vedotin: Phase 3 readout est. (NCT04400695)
DESCRIPTION:Disitamab Vedotin\, phase 3\, HR+/HER2- Metastatic Breast Cance
 r.\nStudy: A Study of RC48-ADC for the Treatment of Locally Advanced or Me
 tastatic Breast Cancer With Low Expression of HER2\nEstimated primary comp
 letion: 31 December 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/disitamab-vedotin#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT04400695
URL:https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07366840-2454@assetmemo.bio
DTSTAMP:20261121T005658Z
DTSTART;VALUE=DATE:20280116
DTEND;VALUE=DATE:20280117
SUMMARY:Disitamab Vedotin: Phase 2/3 readout est. (NCT07366840)
DESCRIPTION:Disitamab Vedotin\, phase 2/3\, HER2-Positive Breast Cancer.\nS
 tudy: RC48 Combined With Chemotherapy in HER2-Positive Advanced Breast Can
 cer Patients With Prior TOP1i-ADC Failure\nEstimated primary completion: 1
 6 January 2028. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/disit
 amab-vedotin#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07366840
URL:https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07879469-2454@assetmemo.bio
DTSTAMP:20261121T005658Z
DTSTART;VALUE=DATE:20280301
DTEND;VALUE=DATE:20280302
SUMMARY:Disitamab Vedotin: Phase 2 readout est. (NCT07879469)
DESCRIPTION:Disitamab Vedotin\, phase 2.\nStudy: Antibody-Drug Conjugate Pl
 us Immunotherapy Versus Immunotherapy Plus Chemotherapy for Extensive Tran
 surethrally Unresectable Very-High-Risk Non-Muscle-Invasive Bladder Cancer
 \nEstimated primary completion: 1 March 2028. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/disitamab-vedotin#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07879469
URL:https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05904964-2454@assetmemo.bio
DTSTAMP:20261121T005658Z
DTSTART;VALUE=DATE:20280301
DTEND;VALUE=DATE:20280302
SUMMARY:Disitamab Vedotin: Phase 3 readout est. (NCT05904964)
DESCRIPTION:Disitamab Vedotin\, phase 3\, HR+/HER2- Metastatic Breast Cance
 r.\nStudy: Disitamab Vedotin (RC48) in Hormone Receptor Positive\, HER2-lo
 w Metastatic Breast Cancer (the Rosy Trial)\nEstimated primary completion:
  1 March 2028. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/disita
 mab-vedotin#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT05904964
URL:https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07507526-2454@assetmemo.bio
DTSTAMP:20261121T005658Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Disitamab Vedotin: Phase 2 readout est. (NCT07507526)
DESCRIPTION:Disitamab Vedotin\, phase 2\, Gastric Cancer.\nStudy: A Study o
 f Disitamab Vedotin\, Tunlametinib\, and PD-1 Antibody for Advanced Gastri
 c Cancer\nEstimated primary completion: 30 April 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07507526
URL:https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06944496-2454@assetmemo.bio
DTSTAMP:20261121T005658Z
DTSTART;VALUE=DATE:20280515
DTEND;VALUE=DATE:20280516
SUMMARY:Disitamab Vedotin: Phase 3 readout est. (NCT06944496)
DESCRIPTION:Disitamab Vedotin\, phase 3.\nStudy: A Study of Disitamab Vedot
 in Combined With Tislelizumab and Chemotherapy Versus Tislelizumab Combine
 d With Chemotherapy in HER2-Low Advanced Gastric or Gastroesophageal Junct
 ion Adenocarcinoma\nEstimated primary completion: 15 May 2028. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/disitamab-vedotin#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06944496
URL:https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07100184-2454@assetmemo.bio
DTSTAMP:20261121T005658Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Disitamab Vedotin: Phase 2 readout est. (NCT07100184)
DESCRIPTION:Disitamab Vedotin\, phase 2.\nStudy: RC48 in Combination With R
 adiotherapy for HER2-Expressing NMIBC Patients\nEstimated primary completi
 on: 31 May 2028. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/disi
 tamab-vedotin#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07100184
URL:https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06210490-2454@assetmemo.bio
DTSTAMP:20261121T005658Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Disitamab Vedotin: Phase 2 readout est. (NCT06210490)
DESCRIPTION:Disitamab Vedotin\, phase 2\, Urothelial Carcinoma.\nStudy: A C
 linical Study of the Efficacy and Safety of Disitamab Vedotin in Combinati
 on With Radiotherapy for the Adjuvant Treatment of HER2 Overexpressing UTU
 C Patients With High Risk Factors for Recurrence After Radical Surgery\nEs
 timated primary completion: 31 May 2028. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/disitamab-vedotin#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT06210490
URL:https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07490990-2454@assetmemo.bio
DTSTAMP:20261121T005658Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Disitamab Vedotin: Phase 2 readout est. (NCT07490990)
DESCRIPTION:Disitamab Vedotin\, phase 2\, Gastric Cancer.\nStudy: Disitamab
  Vedotin Combined With Sintilimab and Multimodal Radiotherapy for HER2-Pos
 itive Advanced Gastric Cancer After Second-Line Treatment Failure: A Prosp
 ective\, Single-Arm Phase II Clinical Trial\nEstimated primary completion:
  June 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/disitamab
 -vedotin#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07490990
URL:https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07717242-2454@assetmemo.bio
DTSTAMP:20261121T005658Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Disitamab Vedotin: Phase 2 readout est. (NCT07717242)
DESCRIPTION:Disitamab Vedotin\, phase 2\, Urothelial Carcinoma.\nStudy: Sun
  Yat-Sen Treatment Strategy for Enhancing Response in Muscle-invasive Blad
 der Cancer\nEstimated primary completion: 30 June 2028. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07717242
URL:https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07693959-2454@assetmemo.bio
DTSTAMP:20261121T005658Z
DTSTART;VALUE=DATE:20280701
DTEND;VALUE=DATE:20280702
SUMMARY:Disitamab Vedotin: Phase 3 readout est. (NCT07693959)
DESCRIPTION:Disitamab Vedotin\, phase 3.\nStudy: Neoadjuvant RC48 Plus Gemc
 itabine in HER2-Expressing MIBC\nEstimated primary completion: 1 July 2028
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/disitamab-vedotin#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07693
 959
URL:https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06145308-2454@assetmemo.bio
DTSTAMP:20261121T005658Z
DTSTART;VALUE=DATE:20280710
DTEND;VALUE=DATE:20280711
SUMMARY:Disitamab Vedotin: Phase 2 readout est. (NCT06145308)
DESCRIPTION:Disitamab Vedotin\, phase 2.\nStudy: Precision Treatment of Rec
 urrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing\nEst
 imated primary completion: 10 July 2028. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/disitamab-vedotin#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT06145308
URL:https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06540729-2454@assetmemo.bio
DTSTAMP:20261121T005658Z
DTSTART;VALUE=DATE:20280801
DTEND;VALUE=DATE:20280802
SUMMARY:Disitamab Vedotin: Phase 2 readout est. (NCT06540729)
DESCRIPTION:Disitamab Vedotin\, phase 2.\nStudy: RC48 in Combination With A
 K104 and Bevacizumab in OCCC\nEstimated primary completion: 1 August 2028.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/disitamab-vedotin#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT065407
 29
URL:https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07194005-2454@assetmemo.bio
DTSTAMP:20261121T005658Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Disitamab Vedotin: Phase 2 readout est. (NCT07194005)
DESCRIPTION:Disitamab Vedotin\, phase 2\, Gastric Cancer.\nStudy: Conversio
 n Therapy With RC48\, Sintilimab\, and SOX for HER2 1+/2+ Unresectable Gas
 tric Cancer\nEstimated primary completion: 30 September 2028. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07194005
URL:https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07474324-2454@assetmemo.bio
DTSTAMP:20261121T005658Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Disitamab Vedotin: Phase 2 readout est. (NCT07474324)
DESCRIPTION:Disitamab Vedotin\, phase 2\, Gastric Cancer.\nStudy: Disitamab
  Vedotin Combined With SOX Regimen Versus SOX Alone as Adjuvant Therapy fo
 r HER2-Moderate/High Expressing Stage Ⅲ Gastric Cancer: A Prospective\, 
 Multicenter\, Randomized\, Phase Ⅱ Clinical Trial\nEstimated primary com
 pletion: 31 December 2028. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/disitamab-vedotin#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07474324
URL:https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06378242-2454@assetmemo.bio
DTSTAMP:20261121T005658Z
DTSTART;VALUE=DATE:20290315
DTEND;VALUE=DATE:20290316
SUMMARY:Disitamab Vedotin: Phase 1/2 readout est. (NCT06378242)
DESCRIPTION:Disitamab Vedotin\, phase 1/2.\nStudy: To Evaluate the Safety\,
  Efficacy\, and Pharmacokinetics of Intravesical Instiliations of Disitama
 b Vedotin in Patients With High-risk Non-muscular Invasive Bladder Cancer 
 (NMIBC) That Express HER2\nEstimated primary completion: 15 March 2029. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/disitamab-vedotin#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT06378242
URL:https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07509424-2454@assetmemo.bio
DTSTAMP:20261121T005658Z
DTSTART;VALUE=DATE:20290410
DTEND;VALUE=DATE:20290411
SUMMARY:Disitamab Vedotin: Phase 2 readout est. (NCT07509424)
DESCRIPTION:Disitamab Vedotin\, phase 2.\nStudy: Neoadjuvant Short-course R
 adiotherapy Followed by a Combination of Disitamab Vedotin\, Sintilimab\, 
 and Capecitabine in Locally Advanced HER2-expressing Rectal Cance\nEstimat
 ed primary completion: 10 April 2029. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/disitamab-vedotin#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07509424
URL:https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07498907-2454@assetmemo.bio
DTSTAMP:20261121T005658Z
DTSTART;VALUE=DATE:20290501
DTEND;VALUE=DATE:20290502
SUMMARY:Disitamab Vedotin: Phase 3 readout est. (NCT07498907)
DESCRIPTION:Disitamab Vedotin\, phase 3\, Urothelial Carcinoma.\nStudy: Dis
 itamab Vedotin Plus Radiotherapy for Adjuvant Treatment of HER2-Expressing
  Cisplatin-Ineligible Upper Tract Urothelial Carcinoma\nEstimated primary 
 completion: 1 May 2029. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/disitamab-vedotin#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07498907
URL:https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07315750-2454@assetmemo.bio
DTSTAMP:20261121T005658Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Disitamab Vedotin: Phase 3 readout est. (NCT07315750)
DESCRIPTION:Disitamab Vedotin\, phase 3.\nStudy: A Study of Disitamab Vedot
 in Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined
  With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Ad
 vanced Gastric or Gastroesophageal Junction Adenocarcinoma.\nEstimated pri
 mary completion: 30 June 2029. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/disitamab-vedotin#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07315750
URL:https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06157892-2454@assetmemo.bio
DTSTAMP:20261121T005658Z
DTSTART;VALUE=DATE:20290728
DTEND;VALUE=DATE:20290729
SUMMARY:Disitamab Vedotin: Phase 2 readout est. (NCT06157892)
DESCRIPTION:Disitamab Vedotin\, phase 2\, Gastric Cancer.\nStudy: A Study o
 f Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors\nEstimated
  primary completion: 28 July 2029. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/disitamab-vedotin#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT06157892
URL:https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07853053-2454@assetmemo.bio
DTSTAMP:20261121T005658Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Disitamab Vedotin: Phase 1 readout est. (NCT07853053)
DESCRIPTION:Disitamab Vedotin\, phase 1.\nStudy: DV Plus Toripalimab With C
 etirizine and Mecobalamin Pretreatment in Patients With Locally Advanced U
 nresectable or Metastatic Bladder Cancer\nEstimated primary completion: 31
  December 2029. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/disit
 amab-vedotin#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07853053
URL:https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07608224-2454@assetmemo.bio
DTSTAMP:20261121T005658Z
DTSTART;VALUE=DATE:20300630
DTEND;VALUE=DATE:20300701
SUMMARY:Disitamab Vedotin: Phase 2/3 readout est. (NCT07608224)
DESCRIPTION:Disitamab Vedotin\, phase 2/3.\nStudy: HOPE-07-MIBC: Disitamab 
 Vedotin Plus Immunotherapy vs Chemoimmunotherapy in Resectable HER2-Expres
 sing MIBC\nEstimated primary completion: 30 June 2030. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07608224
URL:https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07474064-2454@assetmemo.bio
DTSTAMP:20261121T005658Z
DTSTART;VALUE=DATE:20310331
DTEND;VALUE=DATE:20310401
SUMMARY:Disitamab Vedotin: Phase 2 readout est. (NCT07474064)
DESCRIPTION:Disitamab Vedotin\, phase 2.\nStudy: Probiotics Combined With T
 argeted Therapy Plus Immunotherapy in Bladder-Preserving Setting for Patie
 nts With MIBC\nEstimated primary completion: 31 March 2031. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07474064
URL:https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06278870-2454@assetmemo.bio
DTSTAMP:20261121T005658Z
DTSTART;VALUE=DATE:20310630
DTEND;VALUE=DATE:20310701
SUMMARY:Disitamab Vedotin: Phase 3 readout est. (NCT06278870)
DESCRIPTION:Disitamab Vedotin\, phase 3.\nStudy: Disitamab Vedotin + Pyroti
 nib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cance
 r Clinical Trial\nEstimated primary completion: 30 June 2031. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT06278870
URL:https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06417554-2454@assetmemo.bio
DTSTAMP:20261121T005658Z
DTSTART;VALUE=DATE:20311231
DTEND;VALUE=DATE:20320101
SUMMARY:Disitamab Vedotin: Phase 1/2 readout est. (NCT06417554)
DESCRIPTION:Disitamab Vedotin\, phase 1/2.\nStudy: A Trial of SHR-A2102 Wit
 h or Without Antitumor Therapy in Advanced Solid Tumors\nEstimated primary
  completion: 31 December 2031. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/disitamab-vedotin#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT06417554
URL:https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
